Dapagliflozin + sacubitril/valsartan
Dapagliflozin + sacubitril/valsartan has been studied in 3 papers since 2025: 1 observational study in people, 2 in animals; 2 in the past year. The newest paper, Nov 2, 2026: “Therapeutic Effects of Sacubitril/Valsartan and Dapagliflozin on Oxidative Stress and Iron Dysregulation in Monocrotaline-Induced Pulmonary Arterial Hypertension”.
3 papers study it7 findingsUpdated
1 new paper in 30 daysSee all 3 papers on dapagliflozin + sacubitril/valsartan
At a glance
The findings reach people, from one lab or study. 3 independent labs in 3 countries.
“the study group showed a marked increase in LVEF (60.3±6.2 vs 54.1±5.7, P < 0.001)”
None of its findings points the other way.
- 3 independent labs in 3 countries
- Funders: Italian Ministry of University and Research and 1 more
- 2 of 7 findings with company ties
- Humans1
- Animals2
What did studies of dapagliflozin + sacubitril/valsartan find?
6Studies of dapagliflozin + sacubitril/valsartan measured 6 outcomes, among them oxidative stress and ROS signaling, NOS3 and cellular senescence.
Oxidative stress and ROS signaling
downin rats1
1 study
Oxidative stress and ROS signaling
downin rats1
Dapagliflozin + sacubitril/valsartan decreases oxidative stress and ROS signaling in rats (monocrotaline-induced pulmonary arterial hypertension).
“combined Sacubitril/valsartan and dapagliflozin therapy showed a more consistent antioxidative profile.”
Animalsmonocrotaline-induced pulmonary arterial hypertensionplasma
AHA Scientific Sessions 2026 abstract
NOS3
upin rats1
1 study
NOS3
upin rats1
Dapagliflozin + sacubitril/valsartan increases NOS3 in aged female F344 rats with dysmetabolic aging heart failure.
“Only the combination therapy significantly enhanced endothelial nitric oxide synthase (eNOS) expression”
Animalsin aged female F344 rats with dysmetabolic aging heart failureheart45 weeksfemales
Cardiovascular diabetology
Cellular senescence
downin rats1
1 study
Cellular senescence
downin rats1
Dapagliflozin + sacubitril/valsartan decreases cellular senescence in aged female F344 rats with dysmetabolic aging heart failure.
“reduced markers of cellular senescence, including p53 acetylation and p21CIP1”
Animalsin aged female F344 rats with dysmetabolic aging heart failureheart45 weeksfemales
Cardiovascular diabetology
Inflammation
downin humans1
1 study
Inflammation
downin humans1
Dapagliflozin + sacubitril/valsartan decreases inflammation in humans (heart failure post emergency PCI for acute myocardial infarction) (113.25±40.55 vs 142.72±31.20 pg/L).
“in levels of inflammatory factors including (IL-6: 113.25±40.55 vs 142.72±31.20 pg/L, P < 0.001)”
Human trialheart failure post emergency PCI for acute myocardial infarction12 weeksn = 94
American journal of translational research
6-minute walk test
upin humans1
1 study
6-minute walk test
upin humans1
Dapagliflozin + sacubitril/valsartan improves 6-minute walk test in humans (heart failure post emergency PCI for acute myocardial infarction) (447.11±34.08 vs 406.24±31.77 m).
“better performance in 6MWT (447.11±34.08 vs 406.24±31.77 m, P < 0.001)”
Human trialheart failure post emergency PCI for acute myocardial infarction12 weeksn = 94
American journal of translational research
Left ventricular ejection fraction
upin humans1
1 study
Left ventricular ejection fraction
upin humans1
Dapagliflozin + sacubitril/valsartan improves left ventricular ejection fraction in humans (heart failure post emergency PCI for acute myocardial infarction) (60.3±6.2 vs 54.1±5.7).
“the study group showed a marked increase in LVEF (60.3±6.2 vs 54.1±5.7, P < 0.001)”
Human trialheart failure post emergency PCI for acute myocardial infarction12 weeksn = 94
American journal of translational research
What is dapagliflozin + sacubitril/valsartan linked with?
1Studies link dapagliflozin + sacubitril/valsartan with major adverse cardiac events.
Major adverse cardiac events
downin humans1
1 study
Major adverse cardiac events
downin humans1
Dapagliflozin + sacubitril/valsartan lowers the risk of major adverse cardiac events in humans (heart failure post emergency PCI for acute myocardial infarction) (9.80% vs 25.58%).
“patients in the study group demonstrated lower rate of MACE occurrence compared to the control group (9.80% vs 25.58%, P=0.043)”
Human trialheart failure post emergency PCI for acute myocardial infarction12 weeksn = 94
American journal of translational research